Cover image
市場調查報告書 - 227770

奧地利的體外診斷市場預測:臨床化學檢驗·遺傳基因檢驗·血液檢驗·組織/細胞檢驗,免疫化學檢查·感染/免疫疾病檢驗·微生物學培養檢驗

Austria In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

出版商 GlobalData
出版日期 2012年12月28日 內容資訊 英文 264 Pages
價格
奧地利的體外診斷市場預測:臨床化學檢驗·遺傳基因檢驗·血液檢驗·組織/細胞檢驗,免疫化學檢查·感染/免疫疾病檢驗·微生物學培養檢驗 Austria In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture
出版日期: 2012年12月28日 內容資訊: 英文 264 Pages
簡介

本報告提供奧地利的體外診斷市場主要的資料和市場區隔及不同分類的收益,企業佔有率,流通佔有率等調查結果,為您概述為以下內容。

1 目錄

1 目錄

  • 1.1 表格一覽
  • 1.2 圖表一覽

2 簡介

  • 2.1 關於本報告

3 體外診斷 - 奧地利

  • 3.1 體外診斷, 市場區分
  • 3.2 體外診斷, 奧地利, 整體收益 ($m), USD 以實額為基礎, 實際成果及預測
  • 3.3 體外診斷 市場, 奧地利, 綜合收益 ($m)
  • 3.4 體外診斷 市場, 奧地利, 各分類收益貢獻度 (%)
  • 3.5 體外診斷, 奧地利, 企業佔有率

4 臨床化學檢驗 - 奧地利

  • 4.1 臨床化學檢驗, 市場區分
  • 4.2 臨床化學檢驗 市場, 奧地利, 綜合收益 ($m)
  • 4.3 臨床化學檢驗 市場, 奧地利, 不同市場區隔收益貢獻度 (%)
  • 4.4 臨床化學檢驗 整體收益 (實際成果及預測)
    • 4.4.1 臨床化學分析設備 收益 (實際成果及預測)
    • 4.4.2 尿液檢查 收益 (實際成果及預測)
  • 4.5 臨床化學檢驗 流通佔有率
  • 4.6 臨床化學檢驗, 奧地利, 企業佔有率

5 遺傳基因檢驗 - 奧地利

  • 5.1 遺傳基因檢驗, 市場區分
  • 5.2 遺傳基因檢驗 市場, 奧地利, 綜合收益 ($m)
  • 5.3 遺傳基因檢驗 市場, 奧地利, 不同市場區隔收益貢獻度 (%)
  • 5.4 遺傳基因檢驗 整體收益 (實際成果及預測)
  • 5.5 遺傳基因檢驗 流通佔有率
  • 5.6 遺傳基因檢驗, 奧地利, 企業佔有率

6 血液檢驗 - 奧地利

  • 6.1 血液檢驗, 市場區分
  • 6.2 血液檢驗 市場, 奧地利, 綜合收益 ($m)
  • 6.3 血液檢驗 市場, 奧地利, 不同市場區隔收益貢獻度 (%)
  • 6.4 血液檢驗 整體收益 (實際成果及預測)
    • 6.4.1 血液分析試劑 收益 (實際成果及預測)
    • 6.4.2 免疫血液學檢查 收益 (實際成果及預測)
    • 6.4.3 血液凝固檢查 收益 (實際成果及預測)
    • 6.4.4 簡易血液檢驗 收益 (實際成果及預測)
    • 6.4.5 血球計數器 收益 (實際成果及預測)
  • 6.5 血液檢驗 流通佔有率
  • 6.6 血液檢驗, 奧地利, 企業佔有率

7 組織/細胞檢驗 - 奧地利

  • 7.1 組織/細胞檢驗, 市場區分
  • 7.2 組織/細胞檢驗 市場, 奧地利, 綜合收益 ($m)
  • 7.3 組織/細胞檢驗 市場, 奧地利, 不同市場區隔收益貢獻度 (%)
  • 7.4 組織/細胞檢驗 整體收益 (實際成果及預測)
  • 7.5 組織/細胞檢驗 流通佔有率
  • 7.6 組織/細胞檢驗, 奧地利, 企業佔有率

8 免疫化學檢查 - 奧地利

  • 8.1 免疫化學檢查 市場, 奧地利, 綜合收益 ($m)
  • 8.2 免疫化學檢查 市場, 奧地利, 不同市場區隔收益貢獻度 (%)
  • 8.3 免疫化學檢查 整體收益 (實際成果及預測)
    • 8.3.1 疾病專一 免疫化學檢查 收益 (實際成果及預測)
    • 8.3.2 藥物濫用檢測 / 藥毒物檢驗 收益 (實際成果及預測)
    • 8.3.3 內分泌檢查 收益 (實際成果及預測)
    • 8.3.4 藥物治療監測 收益 (實際成果及預測)
    • 8.3.5 免疫化學分析儀 收益 (實際成果及預測)
  • 8.4 免疫化學檢查 流通佔有率
  • 8.5 免疫化學檢查, 奧地利, 企業佔有率

9 感染/免疫疾病檢驗 - 奧地利

  • 9.1 感染/免疫疾病檢驗, 市場區分
  • 9.2 感染/免疫疾病檢驗 市場, 奧地利, 綜合收益 ($m)
  • 9.3 感染/免疫疾病檢驗 市場, 奧地利, 不同市場區隔收益貢獻度 (%)
  • 9.4 感染/免疫疾病檢驗 整體收益 (實際成果及預測)
  • 9.5 感染/免疫疾病檢驗 流通佔有率
  • 9.6 感染/免疫疾病檢驗, 奧地利, 企業佔有率

10 微生物學培養檢驗 - 奧地利

  • 10.1 微生物學培養檢驗, 市場區分
  • 10.2 微生物學培養檢驗 市場, 奧地利, 綜合收益 ($m)
  • 10.3 微生物學培養檢驗 市場, 奧地利, 不同市場區隔收益貢獻度 (%)
  • 10.4 微生物學培養檢驗 整體收益 (實際成果及預測)
    • 10.4.1 微生物檢驗設備 收益 (實際成果及預測)
  • 10.5 微生物學培養檢驗 流通佔有率
  • 10.6 微生物學培養檢驗, 奧地利, 企業佔有率

11 主要企業概要 - 奧地利 體外診斷 市場

  • 11.1 F. Hoffmann-La Roche Ltd.
    • 11.1.1 企業概要
    • 11.1.2 市場佔有率 - 奧地利 體外診斷 市場
  • 11.2 Siemens Healthcare
    • 11.2.1 企業概要
    • 11.2.2 市場佔有率 - 奧地利 體外診斷 市場
  • 11.3 Abbott Laboratories
    • 11.3.1 企業概要
    • 11.3.2 市場佔有率 - 奧地利 體外診斷 市場
  • 11.4 Beckman Coulter, Inc.
    • 11.4.1 企業概要
    • 11.4.2 市場佔有率 - 奧地利 體外診斷 市場
  • 11.5 bioMerieux S.A.
    • 11.5.1 企業概要
    • 11.5.2 市場佔有率 - 奧地利 體外診斷 市場
  • 11.6 Ortho-Clinical Diagnostics Inc.
    • 11.6.1 企業概要
    • 11.6.2 市場佔有率 - 奧地利 體外診斷 市場
  • 11.7 Bio-Rad Laboratories, Inc.
    • 11.7.1 企業概要
  • 11.8 Becton, Dickinson and Company
    • 11.8.1 企業概要
  • 11.9 Sysmex Corporation
    • 11.9.1 企業概要
  • 11.10 Phadia AB
    • 11.10.1 企業概要
  • 11.11 Qiagen N.V.
    • 11.11.1 企業概要
  • 11.12 DiaSorin S.p.A
    • 11.12.1 企業概要
  • 11.13 Alere Inc.
    • 11.13.1 企業概要
  • 11.14 Gen-Probe Incorporated
    • 11.14.1 企業概要
  • 11.15 Danaher Corporation
    • 11.15.1 企業概要
  • 11.16 DIAGNOSTICA STAGO, Inc.
    • 11.16.1 企業概要
  • 11.17 PerkinElmer, Inc.
    • 11.17.1 企業概要
  • 11.18 堀場製作所
    • 11.18.1 企業概要
  • 11.19 Thermo Fisher Scientific Inc.
    • 11.19.1 企業概要
  • 11.20 Grifols, S.A.
    • 11.20.1 企業概要
  • 11.21 Hologic, Inc.
    • 11.21.1 企業概要
  • 11.22 Immucor, Inc.
    • 11.22.1 企業概要
  • 11.23 Life Technologies Corporation
    • 11.23.1 企業概要

12 體外診斷 市場 開發中產品

  • 12.1 臨床化學檢驗 市場 開發中產品
  • 12.2 免疫化學檢查 市場 開發中產品
  • 12.3 血液檢驗 市場 開發中產品
  • 12.4 感染/免疫疾病檢驗 市場 開發中產品
  • 12.5 微生物學培養檢驗 市場 開發中產品
  • 12.6 組織/細胞檢驗 市場 開發中產品
  • 12.7 遺傳基因檢驗 市場 開發中產品

13 財務交易展望

  • 13.1 合作

14 最新趨勢

  • 14.1 策略及產業計畫

15 附錄

  • 15.1 調查對象的市場定義
    • 15.1.1 體外診斷
  • 15.2 調查方法
  • 15.3 二級研究
  • 15.4 主要研究
  • 15.5 資料的模式化
  • 15.6 預測
  • 15.7 專門委員會
  • 15.8 GlobalData 諮詢服務
  • 15.9 貨幣換算
  • 15.10 諮詢方式
  • 15.11 免責聲明

表格一覽

1.1 表格一覽

  • 表格 1: 體外診斷, 奧地利, 整體收益 ($m), USD 以實額為基礎, 實際成果及預測
  • 表格 2: 體外診斷 市場, 奧地利, 各分類收益貢獻度 (%)
  • 表格 3: 體外診斷, 奧地利, 分類間分析, 實際成果及預測
  • 表格 4: 體外診斷, 奧地利, 整體收益 ($m), USD 以實額為基礎, 實際成果
  • 表格 5: 體外診斷, 奧地利, 整體收益 ($m), USD 以實額為基礎,預測
  • 表格 6: 體外診斷, 奧地利, 企業佔有率 各收益 ($m), USD 以實額為基礎
  • 表格 7: 臨床化學檢驗 市場, 奧地利, 不同市場區隔收益貢獻度 (%)
  • 表格 8: 臨床化學檢驗, 奧地利, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
  • 表格 9: 臨床化學檢驗, 奧地利, 收益 ($m), USD 以實額為基礎 不同市場區隔,預測
  • 表格 10: 臨床化學分析設備, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 表格 11: 臨床化學分析設備, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 表格 12: 尿液檢查, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 表格 13: 尿液檢查, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 表格 14: 臨床化學檢驗, 奧地利, 流通佔有率 各收益 ($m), USD 以實額為基礎
  • 表格 15: 臨床化學檢驗, 奧地利, 企業佔有率 各收益 ($m), USD 以實額為基礎
  • 表格 16: 遺傳基因檢驗 市場, 奧地利, 不同市場區隔收益貢獻度 (%)
  • 表格 17: 遺傳基因檢驗, 奧地利, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
  • 表格 18: 遺傳基因檢驗, 奧地利, 收益 ($m), USD 以實額為基礎 不同市場區隔,預測
  • 表格 19: 遺傳基因檢驗, 奧地利, 流通佔有率 各收益 ($m), USD 以實額為基礎
  • 表格 20: 遺傳基因檢驗, 奧地利, 企業佔有率 各收益 ($m), USD 以實額為基礎
  • 表格 21: 血液檢驗 市場, 奧地利, 不同市場區隔收益貢獻度 (%)
  • 表格 22: 血液檢驗, 奧地利, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
  • 表格 23: 血液檢驗, 奧地利, 收益 ($m), USD 以實額為基礎 不同市場區隔,預測
  • 表格 24: 血液分析試劑, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 表格 25: 血液分析試劑, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 表格 26: 免疫血液學檢查, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 表格 27: 免疫血液學檢查, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 表格 28: 血液凝固檢查, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 表格 29: 血液凝固檢查, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 表格 30: 簡易血液檢驗, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 表格 31: 簡易血液檢驗, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 表格 32: 血球計數器, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 表格 33: 血球計數器, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 表格 34: 血液檢驗, 奧地利, 流通佔有率 各收益 ($m), USD 以實額為基礎
  • 表格 35: 血液檢驗, 奧地利, 企業佔有率 各收益 ($m), USD 以實額為基礎
  • 表格 36: 組織/細胞檢驗 市場, 奧地利, 不同市場區隔收益貢獻度 (%)
  • 表格 37: 組織/細胞檢驗, 奧地利, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
  • 表格 38: 組織/細胞檢驗, 奧地利, 收益 ($m), USD 以實額為基礎 不同市場區隔,預測
  • 表格 39: 組織/細胞檢驗, 奧地利, 流通佔有率 各收益 ($m), USD 以實額為基礎
  • 表格 40: 組織/細胞檢驗, 奧地利, 企業佔有率 各收益 ($m), USD 以實額為基礎
  • 表格 41: 免疫化學檢查 市場, 奧地利, 不同市場區隔收益貢獻度 (%)
  • 表格 42: 免疫化學檢查, 奧地利, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
  • 表格 43: 免疫化學檢查, 奧地利, 收益 ($m), USD 以實額為基礎 不同市場區隔,預測
  • 表格 44: 疾病專一 免疫化學檢查, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 表格 45: 疾病專一 免疫化學檢查, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 表格 46: 藥物濫用檢測 / 藥毒物檢驗, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 表格 47: 藥物濫用檢測 / 藥毒物檢驗, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 表格 48: 內分泌檢查, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 表格 49: 內分泌檢查, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 表格 50: 藥物治療監測, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 表格 51: 藥物治療監測, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 表格 52: 免疫化學分析儀, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 表格 53: 免疫化學分析儀, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 表格 54: 免疫化學檢查, 奧地利, 流通佔有率 各收益 ($m), USD 以實額為基礎
  • 表格 55: 免疫化學檢查, 奧地利, 企業佔有率 各收益 ($m), USD 以實額為基礎
  • 表格 56: 感染/免疫疾病檢驗 市場, 奧地利, 不同市場區隔收益貢獻度 (%)
  • 表格 57: 感染/免疫疾病檢驗, 奧地利, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
  • 表格 58: 感染/免疫疾病檢驗, 奧地利, 收益 ($m), USD 以實額為基礎 不同市場區隔,預測
  • 表格 59: 感染/免疫疾病檢驗, 奧地利, 流通佔有率 各收益 ($m), USD 以實額為基礎
  • 表格 60: 感染/免疫疾病檢驗, 奧地利, 企業佔有率 各收益 ($m), USD 以實額為基礎
  • 表格 61: 微生物學培養檢驗 市場, 奧地利, 不同市場區隔收益貢獻度 (%)
  • 表格 62: 微生物學培養檢驗, 奧地利, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
  • 表格 63: 微生物學培養檢驗, 奧地利, 收益 ($m), USD 以實額為基礎 不同市場區隔,預測
  • 表格 64: 微生物檢驗設備, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 表格 65: 微生物檢驗設備, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 表格 66: 微生物學培養檢驗, 奧地利, 流通佔有率 各收益 ($m), USD 以實額為基礎
  • 表格 67: 微生物學培養檢驗, 奧地利, 企業佔有率 各收益 ($m), USD 以實額為基礎
  • 表格 68: 臨床化學檢驗 市場 開發中產品
  • 表格 69: 免疫化學檢查 市場 開發中產品
  • 表格 70: 血液檢驗 市場 開發中產品
  • 表格 71: 感染/免疫疾病檢驗 市場 開發中產品
  • 表格 72: 微生物學培養檢驗 市場 開發中產品
  • 表格 73: 組織/細胞檢驗 市場 開發中產品
  • 表格 74: 遺傳基因檢驗 市場 開發中產品
  • 表格 75∼82: 體外診斷 市場, 奧地利, 交易內容詳細內容
  • 表格 83: 美金V.S.該地貨幣, 奧地利, 平均實質匯率

圖表一覽

1.2 圖表一覽

  • 圖 1: 體外診斷, 市場區分
  • 圖 2: 體外診斷, 奧地利, 整體收益 ($m), USD 以實額為基礎, 實際成果及預測
  • 圖 3: 體外診斷 市場, 奧地利, 綜合收益 ($m)
  • 圖 4: 體外診斷 市場, 奧地利, 各分類收益貢獻度 (%)
  • 圖 5: 體外診斷, 奧地利, 分類間分析, 實際成果及預測
  • 圖 6: 體外診斷, 奧地利, 整體收益 ($m), USD 以實額為基礎, 實際成果
  • 圖 7: 體外診斷, 奧地利, 整體收益 ($m), USD 以實額為基礎,預測
  • 圖 8: 體外診斷, 奧地利, 企業佔有率 (%)
  • 圖 9: 臨床化學檢驗, 市場區分
  • 圖 10: 臨床化學檢驗 市場, 奧地利, 綜合收益 ($m)
  • 圖 11: 臨床化學檢驗 市場, 奧地利, 不同市場區隔收益貢獻度 (%)
  • 圖 12: 臨床化學檢驗, 奧地利, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
  • 圖 13: 臨床化學檢驗, 奧地利, 收益 ($m), USD 以實額為基礎 不同市場區隔,預測
  • 圖 14: 臨床化學分析設備, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 圖 15: 臨床化學分析設備, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 圖 16: 尿液檢查, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 圖 17: 尿液檢查, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 圖 18: 臨床化學檢驗, 奧地利, 企業佔有率 (%)
  • 圖 19: 遺傳基因檢驗, 市場區分
  • 圖 20: 遺傳基因檢驗 市場, 奧地利, 綜合收益 ($m)
  • 圖 21: 遺傳基因檢驗 市場, 奧地利, 不同市場區隔收益貢獻度 (%)
  • 圖 22: 遺傳基因檢驗, 奧地利, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
  • 圖 23: 遺傳基因檢驗, 奧地利, 收益 ($m), USD 以實額為基礎 不同市場區隔,預測
  • 圖 24: 遺傳基因檢驗, 奧地利, 企業佔有率 (%)
  • 圖 25: 血液檢驗, 市場區分
  • 圖 26: 血液檢驗 市場, 奧地利, 綜合收益 ($m)
  • 圖 27: 血液檢驗 市場, 奧地利, 不同市場區隔收益貢獻度 (%)
  • 圖 28: 血液檢驗, 奧地利, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
  • 圖 29: 血液檢驗, 奧地利, 收益 ($m), USD 以實額為基礎 不同市場區隔,預測
  • 圖 30: 血液分析試劑, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 圖 31: 血液分析試劑, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 圖 32: 免疫血液學檢查, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 圖 33: 免疫血液學檢查, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 圖 34: 血液凝固檢查, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 圖 35: 血液凝固檢查, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 圖 36: 簡易血液檢驗, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 圖 37: 簡易血液檢驗, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 圖 38: 血球計數器, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 圖 39: 血球計數器, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 圖 40: 血液檢驗, 奧地利, 企業佔有率 (%)
  • 圖 41: 組織/細胞檢驗, 市場區分
  • 圖 42: 組織/細胞檢驗 市場, 奧地利, 綜合收益 ($m)
  • 圖 43: 組織/細胞檢驗 市場, 奧地利, 不同市場區隔收益貢獻度 (%)
  • 圖 44: 組織/細胞檢驗, 奧地利, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
  • 圖 45: 組織/細胞檢驗, 奧地利, 收益 ($m), USD 以實額為基礎 不同市場區隔,預測
  • 圖 46: 組織/細胞檢驗, 奧地利, 企業佔有率 (%)
  • 圖 47: 免疫化學檢查 市場, 奧地利, 綜合收益 ($m)
  • 圖 48: 免疫化學檢查 市場, 奧地利, 不同市場區隔收益貢獻度 (%)
  • 圖 49: 免疫化學檢查, 奧地利, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
  • 圖 50: 免疫化學檢查, 奧地利, 收益 ($m), USD 以實額為基礎 不同市場區隔,預測
  • 圖 51: 疾病專一 免疫化學檢查, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 圖 52: 疾病專一 免疫化學檢查, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 圖 53: 藥物濫用檢測 / 藥毒物檢驗, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 圖 54: 藥物濫用檢測 / 藥毒物檢驗, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 圖 55: 內分泌檢查, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 圖 56: 內分泌檢查, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 圖 57: 藥物治療監測, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 圖 58: 藥物治療監測, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 圖 59: 免疫化學分析儀, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 圖 60: 免疫化學分析儀, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 圖 61: 免疫化學檢查, 奧地利, 企業佔有率 (%)
  • 圖 62: 感染/免疫疾病檢驗, 市場區分
  • 圖 63: 感染/免疫疾病檢驗 市場, 奧地利, 綜合收益 ($m)
  • 圖 64: 感染/免疫疾病檢驗 市場, 奧地利, 不同市場區隔收益貢獻度 (%)
  • 圖 65: 感染/免疫疾病檢驗, 奧地利, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
  • 圖 66: 感染/免疫疾病檢驗, 奧地利, 收益 ($m), USD 以實額為基礎 不同市場區隔,預測
  • 圖 67: 感染/免疫疾病檢驗, 奧地利, 企業佔有率 (%)
  • 圖 68: 微生物學培養檢驗, 市場區分
  • 圖 69: 微生物學培養檢驗 市場, 奧地利, 綜合收益 ($m)
  • 圖 70: 微生物學培養檢驗 市場, 奧地利, 不同市場區隔收益貢獻度 (%)
  • 圖 71: 微生物學培養檢驗, 奧地利, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
  • 圖 72: 微生物學培養檢驗, 奧地利, 收益 ($m), USD 以實額為基礎 不同市場區隔,預測
  • 圖 73: 微生物檢驗設備, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 圖 74: 微生物檢驗設備, 奧地利, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 圖 75: 微生物學培養檢驗, 奧地利, 企業佔有率 (%)
  • 圖 76: F. Hoffmann-La Roche Ltd., 企業佔有率 (%),奧地利 體外診斷 市場
  • 圖 77: Siemens Healthcare, 企業佔有率 (%),奧地利 體外診斷 市場
  • 圖 78: Abbott Laboratories, 企業佔有率 (%),奧地利 體外診斷 市場
  • 圖 79: Beckman Coulter, Inc., 企業佔有率 (%),奧地利 體外診斷 市場
  • 圖 80: bioMerieux S.A., 企業佔有率 (%),奧地利 體外診斷 市場
  • 圖 81: Ortho-Clinical Diagnostics Inc., 企業佔有率 (%),奧地利 體外診斷 市場

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Abstract

Austria In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

Summary

GlobalData's new report, "Austria In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture" provides key market data on the Austria In Vitro Diagnostics market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within market categories - Immuno Chemistry, Infectious Immunology, Clinical Chemistry, Haematology, Microbiology Culture, Histology And Cytology and Genetic Testing. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

  • Market size and company share data for In Vitro Diagnostics market categories - Immuno Chemistry, Infectious Immunology, Clinical Chemistry, Haematology, Microbiology Culture, Histology And Cytology and Genetic Testing.
  • Annualized market revenues (USD million), volume (units) and average price (USD) data for each of the segments and sub-segments within market categories. Data from 2004 to 2011, forecast forward for 7 years to 2018.
  • 2011 company shares and distribution shares data for each of the market categories.
  • Global corporate-level profiles of key companies operating within the Austria In Vitro Diagnostics market.
  • Key players covered include F. Hoffmann-La Roche Ltd., Siemens Healthcare, Abbott Laboratories, Beckman Coulter, Inc., bioMerieux S.A., Ortho-Clinical Diagnostics Inc. and others.

Reasons to buy

  • Develop business strategies by identifying the key market categories and segments poised for strong growth.
  • Develop market-entry and market expansion strategies.
  • Design competition strategies by identifying who-stands-where in the Austria In Vitro Diagnostics competitive landscape.
  • Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
  • What are the key distribution channels and what's the most preferred mode of product distribution - Identify, understand and capitalize.

TOC

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 9
  • 1.2 List of Figures 13

2 Introduction 16

  • 2.1 What is This Report About? 16

3 In Vitro Diagnostics In Austria 17

  • 3.1 In Vitro Diagnostics, Market Segmentation 17
  • 3.2 In Vitro Diagnostics, Austria, Overall Revenue ($m), USD Constant, 2004-2018 18
  • 3.3 In Vitro Diagnostics Market, Austria, Revenue Mix ($m), 2011 20
  • 3.4 In Vitro Diagnostics Market, Austria, Category Contribution (%), 2011 21
  • 3.5 In Vitro Diagnostics, Austria, Company Share (2010-2011) 28

4 Clinical Chemistry In Austria 30

  • 4.1 Clinical Chemistry, Market Segmentation 30
  • 4.2 Clinical Chemistry Market, Austria, Revenue Mix ($m), 2011 31
  • 4.3 Clinical Chemistry Market, Austria, Segment Contribution (%), 2011 32
  • 4.4 Clinical Chemistry Overall Revenue, (2004-2018) 33
    • 4.4.1 Clinical Chemisty Analyzers, Revenue (2004-2018) 37
    • 4.4.2 Urine Analysis, Revenue (2004-2018) 41
  • 4.5 Clinical Chemistry Distribution Share (2010-2011) 45
  • 4.6 Clinical Chemistry, Austria, Company Share (2010-2011) 46

5 Genetic Testing In Austria 48

  • 5.1 Genetic Testing, Market Segmentation 48
  • 5.2 Genetic Testing Market, Austria, Revenue Mix ($m), 2011 49
  • 5.3 Genetic Testing Market, Austria, Segment Contribution (%), 2011 50
  • 5.4 Genetic Testing Overall Revenue, (2004-2018) 51
  • 5.5 Genetic Testing Distribution Share (2010-2011) 55
  • 5.6 Genetic Testing, Austria, Company Share (2010-2011) 56

6 Haematology In Austria 58

  • 6.1 Haematology Market, Market Segmentation 58
  • 6.2 Haematology Market, Austria, Revenue Mix ($m), 2011 59
  • 6.3 Haematology Market, Austria, Segment Contribution (%), 2011 60
  • 6.4 Haematology Overall Revenue, (2004-2018) 61
    • 6.4.1 Haematology Reagents, Revenue (2004-2018) 65
    • 6.4.2 Immunohaematology, Revenue (2004-2018) 69
    • 6.4.3 Haemostasis, Revenue (2004-2018) 73
    • 6.4.4 Haematology Rapid Tests, Revenue (2004-2018) 77
    • 6.4.5 Haematology Cell Counters, Revenue (2004-2018) 81
  • 6.5 Haematology Distribution Share (2010-2011) 85
  • 6.6 Haematology, Austria, Company Share (2010-2011) 86

7 Histology And Cytology In Austria 88

  • 7.1 Histology and Cytology Market, Market Segmentation 88
  • 7.2 Histology And Cytology Market, Austria, Revenue Mix ($m), 2011 89
  • 7.3 Histology And Cytology Market, Austria, Segment Contribution (%), 2011 90
  • 7.4 Histology And Cytology Overall Revenue, (2004-2018) 91
  • 7.5 Histology And Cytology Distribution Share (2010-2011) 95
  • 7.6 Histology And Cytology, Austria, Company Share (2010-2011) 96

8 Immuno Chemistry In Austria 98

  • 8.1 Immuno Chemistry Market, Austria, Revenue Mix ($m), 2011 98
  • 8.2 Immuno Chemistry Market, Austria, Segment Contribution (%), 2011 99
  • 8.3 Immuno Chemistry Overall Revenue, (2004-2018) 100
    • 8.3.1 Disease Specific Immunochemistry, Revenue (2004-2018) 104
    • 8.3.2 Drugs of Abuse / Toxicology, Revenue (2004-2018) 108
    • 8.3.3 Endocrinology Tests, Revenue (2004-2018) 112
    • 8.3.4 Immunochemistry Rapid Tests, Revenue (2004-2018) 116
    • 8.3.5 Therapeutic Drug Monitoring, Revenue (2004-2018) 120
    • 8.3.6 Immunochemistry Analyzers, Revenue (2004-2018) 124
  • 8.4 Immuno Chemistry Distribution Share (2010-2011) 128
  • 8.5 Immuno Chemistry, Austria, Company Share (2010-2011) 129

9 Infectious Immunology In Austria 131

  • 9.1 Infectious Immunology, Market Segmentation 131
  • 9.2 Infectious Immunology Market, Austria, Revenue Mix ($m), 2011 132
  • 9.3 Infectious Immunology Market, Austria, Segment Contribution (%), 2011 133
  • 9.4 Infectious Immunology Overall Revenue, (2004-2018) 134
    • 9.4.1 Infectious Immunology Rapid Tests, Revenue (2004-2018) 138
  • 9.5 Infectious Immunology Distribution Share (2010-2011) 142
  • 9.6 Infectious Immunology, Austria, Company Share (2010-2011) 143

10 Microbiology Culture In Austria 145

  • 10.1 Microbiology Culture, Market Segmentation 145
  • 10.2 Microbiology Culture Market, Austria, Revenue Mix ($m), 2011 146
  • 10.3 Microbiology Culture Market, Austria, Segment Contribution (%), 2011 147
  • 10.4 Microbiology Culture Overall Revenue, (2004-2018) 148
    • 10.4.1 Microbiology Analyzers, Revenue (2004-2018) 152
  • 10.5 Microbiology Culture Distribution Share (2010-2011) 156
  • 10.6 Microbiology Culture, Austria, Company Share (2010-2011) 157

11 Overview of Key Companies in Austria In Vitro Diagnostics Market 159

  • 11.1 F. Hoffmann-La Roche Ltd. 159
    • 11.1.1 Company Overview 159
    • 11.1.2 Share in the Austria In Vitro Diagnostics Market 159
  • 11.2 Siemens Healthcare 160
    • 11.2.1 Company Overview 160
    • 11.2.2 Share in the Austria In Vitro Diagnostics Market 160
  • 11.3 Abbott Laboratories 161
    • 11.3.1 Company Overview 161
    • 11.3.2 Share in the Austria In Vitro Diagnostics Market 161
  • 11.4 Beckman Coulter, Inc. 162
    • 11.4.1 Company Overview 162
    • 11.4.2 Share in the Austria In Vitro Diagnostics Market 162
  • 11.5 bioMerieux S.A. 163
    • 11.5.1 Company Overview 163
    • 11.5.2 Share in the Austria In Vitro Diagnostics Market 163
  • 11.6 Ortho-Clinical Diagnostics Inc. 164
    • 11.6.1 Company Overview 164
    • 11.6.2 Share in the Austria In Vitro Diagnostics Market 164
  • 11.7 Bio-Rad Laboratories, Inc. 165
    • 11.7.1 Company Overview 165
  • 11.8 Sysmex Corporation 165
    • 11.8.1 Company Overview 165
  • 11.9 Alere Inc. 166
    • 11.9.1 Company Overview 166
  • 11.10 Becton, Dickinson and Company 166
    • 11.10.1 Company Overview 166
  • 11.11 Qiagen N.V. 167
    • 11.11.1 Company Overview 167
  • 11.12 DiaSorin S.p.A 167
    • 11.12.1 Company Overview 167
  • 11.13 Gen-Probe Incorporated 168
    • 11.13.1 Company Overview 168
  • 11.14 Danaher Corporation 168
    • 11.14.1 Company Overview 168
  • 11.15 Diagnostica Stago, Inc. 169
    • 11.15.1 Company Overview 169
  • 11.16 PerkinElmer, Inc. 169
    • 11.16.1 Company Overview 169
  • 11.17 Thermo Fisher Scientific Inc. 170
    • 11.17.1 Company Overview 170
  • 11.18 Horiba, Ltd. 170
    • 11.18.1 Company Overview 170
  • 11.19 Grifols, S.A. 171
    • 11.19.1 Company Overview 171
  • 11.20 Immucor, Inc. 171
    • 11.20.1 Company Overview 171
  • 11.21 Phadia AB 172
    • 11.21.1 Company Overview 172
  • 11.22 Life Technologies Corporation 172
    • 11.22.1 Company Overview 172

12 In Vitro Diagnostics Market Pipeline Products 173

  • 12.1 Clinical Chemisty Market Pipeline Products 173
  • 12.2 Immuno Chemistry Market Pipeline Products 176
  • 12.3 Haematology Market Pipeline Products 185
  • 12.4 Infectious Immunology Market Pipeline Products 187
  • 12.5 Microbiology Culture Market Pipeline Products 194
  • 12.6 Histology And Cytology Market Pipeline Products 195
  • 12.7 Genetic Testing Market Pipeline Products 196

13 Financial Deals Landscape 201

  • 13.1 Partnerships 201
    • 13.1.1 Cisbio Bioassays Enters Into Distribution Agreement With BellBrook Labs For Transcreener Epigen Methyltransferase Assay 201
    • 13.1.2 bioMerieux Enters Into Licensing Agreement With Quanterix For Simoa Technology 203
    • 13.1.3 Affinity Biosensors Enters Into Distribution Agreement With Malvern Instruments For Archimedes Particle Metrology System 205
    • 13.1.4 Agenix Enters Into Licensing Agreement With Tyrian Diagnostics For DiagnostIQ 206
    • 13.1.5 BioDot Enters Into Co-Marketing Agreement With JOT Automation 207
    • 13.1.6 BD Diagnostic Systems Enters Into Agreement With Lab21 To Develop New Oncology Assays 208
    • 13.1.7 CellaVision Enters Into Distribution Agreement With Siemens Healthcare For Digital Microscopy Hematology Solutions 209
    • 13.1.8 Med BioGene Amends Licensing Agreement With Precision Therapeutics For LungExpress Dx Test 211
    • 13.1.9 Ovizio Imaging Systems Enters Into Distribution Agreement With Applikon Biotechnology 213
    • 13.1.10 Life Technologies Enters Into Co-Marketing Agreement With Pathogenica 214
    • 13.1.11 CML HealthCare Enters Into Agreement With MaRS Innovation 215
    • 13.1.12 Akrivis Technologies Enters Into Co-Development Agreement With United States Biological 216
    • 13.1.13 Castle Biosciences Enters Into Licensing Agreement With Brigham and Women's Hospital For Mesothelioma Test 217
    • 13.1.14 Scienion Enters Into Co-Marketing Agreement With Maine Manufacturing For Protein Array Products 218
    • 13.1.15 GeneCentric Diagnostics Enters Into Licensing Agreement With University of North Carolina 219
    • 13.1.16 Epistem Enters Into Distribution Agreement With Becton Dickinson For Mycobacterium TB Test 220
    • 13.1.17 SciFluor Life Sciences Enters Into Distribution Agreement With Sigma-Aldrich For PhenoFluor 221
    • 13.1.18 Immuno-Biological Labs Enters Into Licensing Agreement With IBL International 222
    • 13.1.19 MDxHealth Enters Into Licensing Agreement With Merck For MGMT Diagnostic Test 223
    • 13.1.20 Kreatech Diagnostics Enters Into Co-Development Agreement With Oridis Biomarkers For DNA-FISH Assays 224
    • 13.1.21 NicOx Enters Into Licensing Agreement With Rapid Pathogen Screening For AdenoPlus 225
    • 13.1.22 Immunexpress Enters Into Licensing Agreement With Debiopharm And Biocartis 226
    • 13.1.23 Omega Diagnostics Enters Into Licensing Agreement With Burnet Institute For CD4 POC Test 227
    • 13.1.24 One Lambda Enters Into Co-Marketing Agreement With CellTrend 228
    • 13.1.25 Clarient Diagnostic Services Enters Into Licensing Agreement With Insight Genetics For ALK Cancer Biomarker 229
    • 13.1.26 Affymetrix Enters Into Technology Integration Agreement With Leica Microsystems 230
    • 13.1.27 Ventana Medical Enters Into Licensing Agreement With Gen-Probe For IP Of ERG Marker 231
    • 13.1.28 Affymetrix Enters Into Distribution Agreement With ScreenCell For Circulating Tumor Cell Technology 232
    • 13.1.29 Hycor Biomedical Enters Into Distribution Agreement With Roche For KOVA 233
    • 13.1.30 Nanosphere Enters Into Co-Marketing Agreement With Thermo Fisher For Verigene Products 234
    • 13.1.31 Genome Diagnostics Enters Into Co-Marketing Agreement With Qiagen For LongRange PCR Kit 235
    • 13.1.32 Biofortuna Extends Co-Marketing Agreement With Abbott Labs For SSPGo 236
    • 13.1.33 Pressure BioSciences Enters Into Licensing Agreement With Target Discovery For Pressure Cycling Technology 237
    • 13.1.34 LipoScience Enters Into Licensing Agreement With Cleveland Clinic 238
    • 13.1.35 GE Healthcare Enters Into Co-Development Agreement With NXT2B For Compact Cyclotron And PET Tracer System 239
    • 13.1.36 NexDx Enters Into Licensing Agreement With University of California For Epigenetic Biomarkers 240
    • 13.1.37 Bio-Rad Labs Extends Distribution Agreement With Luminex For MAGPIX 241
    • 13.1.38 Thermo Fisher Scientific Enters Into Distribution Agreement With Abbott For PCT Assay For Sepsis 242
    • 13.1.39 Roche Enters Into Co-Development Agreement With Technoclone 243
    • 13.1.40 Amorfix Life Sciences Enters Into Licensing Agreement With JSW-Lifesciences 244
    • 13.1.41 Sony DADC Enters Into Co-Development Agreement With Axela 246
    • 13.1.42 Sony DADC BioSciences Enters Into Co-Development Agreement With Maven Biotechnologies 247

14 Recent Developments 248

  • 14.1 Product News 248
    • 14.1.1 Sep 28, 2012: Anagnostics Announces Availability Of hybcell Pathogens DNA plexA As CE-IVD Test 248
    • 14.1.2 Sep 27, 2011: Data From Evaluation Of Asuragen's Signature LTx Leukemia Test To Be Presented At Upcoming Planet XMAP In Vienna, Austria 248

15 Appendix 249

  • 15.1 Definitions of Markets Covered in the Report 250
    • 15.1.1 In Vitro Diagnostics 250
  • 15.2 Research Methodology 261
  • 15.3 Secondary Research 261
  • 15.4 Primary Research 262
  • 15.5 Models 262
  • 15.6 Forecasts 263
  • 15.7 Expert Panels 263
  • 15.8 GlobalData Consulting 263
  • 15.9 Currency Conversion 264
  • 15.10 Contact Us 264
  • 15.11 Disclaimer 264

List of Tables

1.1 List of Tables

  • Table 1: In Vitro Diagnostics, Austria, Overall Revenue ($m), USD Constant, 2004-2018 19
  • Table 2: In Vitro Diagnostics Market, Austria, Category Contribution (%), 2011 21
  • Table 3: In Vitro Diagnostics Market, Austria, Cross-Category Analysis, 2004-2018 23
  • Table 4: In Vitro Diagnostics, Austria, Overall Revenue ($m), USD Constant, Historic, 2004-2011 25
  • Table 5: In Vitro Diagnostics, Austria, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 27
  • Table 6: In Vitro Diagnostics, Austria, Company Share by Revenue ($m), USD Constant, 2010-2011 29
  • Table 7: Clinical Chemistry Market, Austria, Segment Contribution (%), 2011 32
  • Table 8: Clinical Chemistry, Austria, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 34
  • Table 9: Clinical Chemistry, Austria, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 36
  • Table 10: Clinical Chemisty Analyzers, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 38
  • Table 11: Clinical Chemisty Analyzers, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 40
  • Table 12: Urine Analysis, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 42
  • Table 13: Urine Analysis, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 44
  • Table 14: Clinical Chemistry, Austria, Distribution Share by Revenue ($m), USD Constant, 2010-2011 45
  • Table 15: Clinical Chemistry, Austria, Company Share by Revenue ($m), USD Constant, 2010-2011 47
  • Table 16: Genetic Testing Market, Austria, Segment Contribution (%), 2011 50
  • Table 17: Genetic Testing, Austria, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 52
  • Table 18: Genetic Testing, Austria, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 54
  • Table 19: Genetic Testing, Austria, Distribution Share by Revenue ($m), USD Constant, 2010-2011 55
  • Table 20: Genetic Testing, Austria, Company Share by Revenue ($m), USD Constant, 2010-2011 57
  • Table 21: Haematology Market, Austria, Segment Contribution (%), 2011 60
  • Table 22: Haematology, Austria, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 62
  • Table 23: Haematology, Austria, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 64
  • Table 24: Haematology Reagents, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 66
  • Table 25: Haematology Reagents, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 68
  • Table 26: Immunohaematology, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 70
  • Table 27: Immunohaematology, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 72
  • Table 28: Haemostasis, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 74
  • Table 29: Haemostasis, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 76
  • Table 30: Haematology Rapid Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 78
  • Table 31: Haematology Rapid Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 80
  • Table 32: Haematology Cell Counters, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 82
  • Table 33: Haematology Cell Counters, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 84
  • Table 34: Haematology, Austria, Distribution Share by Revenue ($m), USD Constant, 2010-2011 85
  • Table 35: Haematology, Austria, Company Share by Revenue ($m), USD Constant, 2010-2011 87
  • Table 36: Histology And Cytology Market, Austria, Segment Contribution (%), 2011 90
  • Table 37: Histology And Cytology, Austria, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 92
  • Table 38: Histology And Cytology, Austria, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 94
  • Table 39: Histology And Cytology, Austria, Distribution Share by Revenue ($m), USD Constant, 2010-2011 95
  • Table 40: Histology And Cytology, Austria, Company Share by Revenue ($m), USD Constant, 2010-2011 97
  • Table 41: Immuno Chemistry Market, Austria, Segment Contribution (%), 2011 99
  • Table 42: Immuno Chemistry, Austria, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 101
  • Table 43: Immuno Chemistry, Austria, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 103
  • Table 44: Disease Specific Immunochemistry, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 105
  • Table 45: Disease Specific Immunochemistry, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 107
  • Table 46: Drugs of Abuse / Toxicology, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 109
  • Table 47: Drugs of Abuse / Toxicology, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 111
  • Table 48: Endocrinology Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 113
  • Table 49: Endocrinology Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 115
  • Table 50: Immunochemistry Rapid Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 117
  • Table 51: Immunochemistry Rapid Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 119
  • Table 52: Therapeutic Drug Monitoring, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 121
  • Table 53: Therapeutic Drug Monitoring, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 123
  • Table 54: Immunochemistry Analyzers, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 125
  • Table 55: Immunochemistry Analyzers, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 127
  • Table 56: Immuno Chemistry, Austria, Distribution Share by Revenue ($m), USD Constant, 2010-2011 128
  • Table 57: Immuno Chemistry, Austria, Company Share by Revenue ($m), USD Constant, 2010-2011 130
  • Table 58: Infectious Immunology Market, Austria, Segment Contribution (%), 2011 133
  • Table 59: Infectious Immunology, Austria, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 135
  • Table 60: Infectious Immunology, Austria, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 137
  • Table 61: Infectious Immunology Rapid Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 139
  • Table 62: Infectious Immunology Rapid Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 141
  • Table 63: Infectious Immunology, Austria, Distribution Share by Revenue ($m), USD Constant, 2010-2011 142
  • Table 64: Infectious Immunology, Austria, Company Share by Revenue ($m), USD Constant, 2010-2011 144
  • Table 65: Microbiology Culture Market, Austria, Segment Contribution (%), 2011 147
  • Table 66: Microbiology Culture, Austria, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 149
  • Table 67: Microbiology Culture, Austria, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 151
  • Table 68: Microbiology Analyzers, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 153
  • Table 69: Microbiology Analyzers, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 155
  • Table 70: Microbiology Culture, Austria, Distribution Share by Revenue ($m), USD Constant, 2010-2011 156
  • Table 71: Microbiology Culture, Austria, Company Share by Revenue ($m), USD Constant, 2010-2011 158
  • Table 72: Clinical Chemisty Market Pipeline Products 173
  • Table 73: Immuno Chemistry Market Pipeline Products 176
  • Table 74: Haematology Market Pipeline Products 185
  • Table 75: Infectious Immunology Market Pipeline Products 187
  • Table 76: Microbiology Culture Market Pipeline Products 194
  • Table 77: Histology And Cytology Market Pipeline Products 195
  • Table 78: Genetic Testing Market Pipeline Products 196
  • Table 79: Cisbio Bioassays Enters Into Distribution Agreement With BellBrook Labs For Transcreener Epigen Methyltransferase Assay 201
  • Table 80: bioMerieux Enters Into Licensing Agreement With Quanterix For Simoa Technology 203
  • Table 81: Affinity Biosensors Enters Into Distribution Agreement With Malvern Instruments For Archimedes Particle Metrology System 205
  • Table 82: Agenix Enters Into Licensing Agreement With Tyrian Diagnostics For DiagnostIQ 206
  • Table 83: BioDot Enters Into Co-Marketing Agreement With JOT Automation 207
  • Table 84: BD Diagnostic Systems Enters Into Agreement With Lab21 To Develop New Oncology Assays 208
  • Table 85: CellaVision Enters Into Distribution Agreement With Siemens Healthcare For Digital Microscopy Hematology Solutions 209
  • Table 86: Med BioGene Amends Licensing Agreement With Precision Therapeutics For LungExpress Dx Test 211
  • Table 87: Ovizio Imaging Systems Enters Into Distribution Agreement With Applikon Biotechnology 213
  • Table 88: Life Technologies Enters Into Co-Marketing Agreement With Pathogenica 214
  • Table 89: CML HealthCare Enters Into Agreement With MaRS Innovation 215
  • Table 90: Akrivis Technologies Enters Into Co-Development Agreement With United States Biological 216
  • Table 91: Castle Biosciences Enters Into Licensing Agreement With Brigham and Women's Hospital For Mesothelioma Test 217
  • Table 92: Scienion Enters Into Co-Marketing Agreement With Maine Manufacturing For Protein Array Products 218
  • Table 93: GeneCentric Diagnostics Enters Into Licensing Agreement With University of North Carolina 219
  • Table 94: Epistem Enters Into Distribution Agreement With Becton Dickinson For Mycobacterium TB Test 220
  • Table 95: SciFluor Life Sciences Enters Into Distribution Agreement With Sigma-Aldrich For PhenoFluor 221
  • Table 96: Immuno-Biological Labs Enters Into Licensing Agreement With IBL International 222
  • Table 97: MDxHealth Enters Into Licensing Agreement With Merck For MGMT Diagnostic Test 223
  • Table 98: Kreatech Diagnostics Enters Into Co-Development Agreement With Oridis Biomarkers For DNA-FISH Assays 224
  • Table 99: NicOx Enters Into Licensing Agreement With Rapid Pathogen Screening For AdenoPlus 225
  • Table 100: Immunexpress Enters Into Licensing Agreement With Debiopharm And Biocartis 226
  • Table 101: Omega Diagnostics Enters Into Licensing Agreement With Burnet Institute For CD4 POC Test 227
  • Table 102: One Lambda Enters Into Co-Marketing Agreement With CellTrend 228
  • Table 103: Clarient Diagnostic Services Enters Into Licensing Agreement With Insight Genetics For ALK Cancer Biomarker 229
  • Table 104: Affymetrix Enters Into Technology Integration Agreement With Leica Microsystems 230
  • Table 105: Ventana Medical Enters Into Licensing Agreement With Gen-Probe For IP Of ERG Marker 231
  • Table 106: Affymetrix Enters Into Distribution Agreement With ScreenCell For Circulating Tumor Cell Technology 232
  • Table 107: Hycor Biomedical Enters Into Distribution Agreement With Roche For KOVA 233
  • Table 108: Nanosphere Enters Into Co-Marketing Agreement With Thermo Fisher For Verigene Products 234
  • Table 109: Genome Diagnostics Enters Into Co-Marketing Agreement With Qiagen For LongRange PCR Kit 235
  • Table 110: Biofortuna Extends Co-Marketing Agreement With Abbott Labs For SSPGo 236
  • Table 111: Pressure BioSciences Enters Into Licensing Agreement With Target Discovery For Pressure Cycling Technology 237
  • Table 112: LipoScience Enters Into Licensing Agreement With Cleveland Clinic 238
  • Table 113: GE Healthcare Enters Into Co-Development Agreement With NXT2B For Compact Cyclotron And PET Tracer System 239
  • Table 114: NexDx Enters Into Licensing Agreement With University of California For Epigenetic Biomarkers 240
  • Table 115: Bio-Rad Labs Extends Distribution Agreement With Luminex For MAGPIX 241
  • Table 116: Thermo Fisher Scientific Enters Into Distribution Agreement With Abbott For PCT Assay For Sepsis 242
  • Table 117: Roche Enters Into Co-Development Agreement With Technoclone 243
  • Table 118: Amorfix Life Sciences Enters Into Licensing Agreement With JSW-Lifesciences 244
  • Table 119: Sony DADC Enters Into Co-Development Agreement With Axela 246
  • Table 120: Sony DADC BioSciences Enters Into Co-Development Agreement With Maven Biotechnologies 247

List of Figures

1.2 List of Figures

  • Figure 1: In Vitro Diagnostics, Market Segmentation 17
  • Figure 2: In Vitro Diagnostics, Austria, Overall Revenue ($m), USD Constant, 2004-2018 18
  • Figure 3: In Vitro Diagnostics Market, Austria, Revenue Mix ($m), 2011 20
  • Figure 4: In Vitro Diagnostics Market, Austria, Category Contribution (%), 2011 21
  • Figure 5: In Vitro Diagnostics Market Austria, Cross-Category Analysis, 2004-2018 22
  • Figure 6: In Vitro Diagnostics, Austria, Overall Revenue ($m), USD Constant, Historic, 2004-2011 24
  • Figure 7: In Vitro Diagnostics, Austria, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 26
  • Figure 8: In Vitro Diagnostics, Austria, Company Share (%), 2011 28
  • Figure 9: Clinical Chemistry, Market Segmentation 30
  • Figure 10: Clinical Chemistry Market, Austria, Revenue Mix ($m), 2011 31
  • Figure 11: Clinical Chemistry Market, Austria, Segment Contribution (%), 2011 32
  • Figure 12: Clinical Chemistry, Austria, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 33
  • Figure 13: Clinical Chemistry, Austria, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 35
  • Figure 14: Clinical Chemisty Analyzers, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 37
  • Figure 15: Clinical Chemisty Analyzers, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 39
  • Figure 16: Urine Analysis, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 41
  • Figure 17: Urine Analysis, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 43
  • Figure 18: Clinical Chemistry, Austria, Company Share (%), 2011 46
  • Figure 19: Genetic Testing, Market Segmentation 48
  • Figure 20: Genetic Testing Market, Austria, Revenue Mix ($m), 2011 49
  • Figure 21: Genetic Testing Market, Austria, Segment Contribution (%), 2011 50
  • Figure 22: Genetic Testing, Austria, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 51
  • Figure 23: Genetic Testing, Austria, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 53
  • Figure 24: Genetic Testing, Austria, Company Share (%), 2011 56
  • Figure 25: Haematology Market, Market Segmentation 58
  • Figure 26: Haematology Market, Austria, Revenue Mix ($m), 2011 59
  • Figure 27: Haematology Market, Austria, Segment Contribution (%), 2011 60
  • Figure 28: Haematology, Austria, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 61
  • Figure 29: Haematology, Austria, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 63
  • Figure 30: Haematology Reagents, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 65
  • Figure 31: Haematology Reagents, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 67
  • Figure 32: Immunohaematology, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 69
  • Figure 33: Immunohaematology, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 71
  • Figure 34: Haemostasis, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 73
  • Figure 35: Haemostasis, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 75
  • Figure 36: Haematology Rapid Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 77
  • Figure 37: Haematology Rapid Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 79
  • Figure 38: Haematology Cell Counters, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 81
  • Figure 39: Haematology Cell Counters, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 83
  • Figure 40: Haematology, Austria, Company Share (%), 2011 86
  • Figure 41: Histology and Cytology Market, Market Segmentation 88
  • Figure 42: Histology And Cytology Market, Austria, Revenue Mix ($m), 2011 89
  • Figure 43: Histology And Cytology Market, Austria, Segment Contribution (%), 2011 90
  • Figure 44: Histology And Cytology, Austria, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 91
  • Figure 45: Histology And Cytology, Austria, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 93
  • Figure 46: Histology And Cytology, Austria, Company Share (%), 2011 96
  • Figure 47: Immuno Chemistry Market, Austria, Revenue Mix ($m), 2011 98
  • Figure 48: Immuno Chemistry Market, Austria, Segment Contribution (%), 2011 99
  • Figure 49: Immuno Chemistry, Austria, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 100
  • Figure 50: Immuno Chemistry, Austria, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 102
  • Figure 51: Disease Specific Immunochemistry, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 104
  • Figure 52: Disease Specific Immunochemistry, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 106
  • Figure 53: Drugs of Abuse / Toxicology, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 108
  • Figure 54: Drugs of Abuse / Toxicology, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 110
  • Figure 55: Endocrinology Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 112
  • Figure 56: Endocrinology Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 114
  • Figure 57: Immunochemistry Rapid Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 116
  • Figure 58: Immunochemistry Rapid Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 118
  • Figure 59: Therapeutic Drug Monitoring, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 120
  • Figure 60: Therapeutic Drug Monitoring, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 122
  • Figure 61: Immunochemistry Analyzers, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 124
  • Figure 62: Immunochemistry Analyzers, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 126
  • Figure 63: Immuno Chemistry, Austria, Company Share (%), 2011 129
  • Figure 64: Infectious Immunology, Market Segmentation 131
  • Figure 65: Infectious Immunology Market, Austria, Revenue Mix ($m), 2011 132
  • Figure 66: Infectious Immunology Market, Austria, Segment Contribution (%), 2011 133
  • Figure 67: Infectious Immunology, Austria, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 134
  • Figure 68: Infectious Immunology, Austria, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 136
  • Figure 69: Infectious Immunology Rapid Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 138
  • Figure 70: Infectious Immunology Rapid Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 20011-2018 140
  • Figure 71: Infectious Immunology, Austria, Company Share (%), 2011 143
  • Figure 72: Microbiology Culture, Market Segmentation 145
  • Figure 73: Microbiology Culture Market, Austria, Revenue Mix ($m), 2011 146
  • Figure 74: Microbiology Culture Market, Austria, Segment Contribution (%), 2011 147
  • Figure 75: Microbiology Culture, Austria, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 148
  • Figure 76: Microbiology Culture, Austria, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 150
  • Figure 77: Microbiology Analyzers, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 152
  • Figure 78: Microbiology Analyzers, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 154
  • Figure 79: Microbiology Culture, Austria, Company Share (%), 2011 157
  • Figure 80: F. Hoffmann-La Roche Ltd., Company Share (%),Austria In Vitro Diagnostics Market, 2011 159
  • Figure 81: Siemens Healthcare, Company Share (%),Austria In Vitro Diagnostics Market, 2011 160
  • Figure 82: Abbott Laboratories, Company Share (%),Austria In Vitro Diagnostics Market, 2011 161
  • Figure 83: Beckman Coulter, Inc., Company Share (%),Austria In Vitro Diagnostics Market, 2011 162
  • Figure 84: bioMerieux S.A., Company Share (%),Austria In Vitro Diagnostics Market, 2011 163
  • Figure 85: Ortho-Clinical Diagnostics Inc., Company Share (%),Austria In Vitro Diagnostics Market, 2011 164

奧地利的體外診斷市場預測:臨床化學檢驗·遺傳基因檢驗·血液檢驗·組織/細胞檢驗,免疫化學檢查·感染/免疫疾病檢驗·微生物學培養檢驗是由出版商GlobalData在2012年12月28日所出版的。這份市場調查報告書包含264 Pages 價格從美金2500起跳。

Back to Top
;